Diaceutics (LSE:DXRX) returned to profitability in the year to 31 December 2025, with adjusted EBITDA up 80% to £7.6m and profit before tax of £0.3m as revenue increased 20% to £38.4m year-on-year.
The diagnostics and commercialisation technology provider recorded annual recurring revenue of £20m (19% growth), net revenue retention of 105% on a constant currency basis and a record order book of £38.9m, providing strong visibility into 2026.
"This performance is testament to the resilience of our platform model and the growing importance of diagnostic intelligence in helping customers identify patients and improve therapy adoption", Chief Executive Ryan Keeling said.
Commercial progress included a second multi-year PMx commercialisation partnership signed in Q4, PMx contracts contributing £2.6m and £1.7m respectively to ARR at 31 December, and continued enterprise engagement with 18 of the top 20 global pharma companies.
The Group said its programmes influenced diagnostic testing and treatment decisions for 970,000 patients in 2025 and that Q1 2026 trading performed in line with the Board's expectations with constant currency revenue growth of 15% versus Q1 2025, leaving the Board confident that its targets for 2026 are on track.
